The capacity of IM to inhibit non-BCR/ABL1 targets has expanded its use to treatment of malignancies driven by KIT mutations, which has been implicated in CML pathogenesis. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.